There are an estimated 170 million people globally infected with hepatitis C virus (HCV), which poses a rising threat to healthcare systems. While some national governments and non-governmental organizations have accelerated efforts to improve HCV education, testing, and treatment, significant barriers remain. Effective disease surveillance is critical but data on chronic HCV prevalence is lacking in over half of countries surveyed. As awareness of HCV has increased, patient advocacy groups have played a leading role in shaping policy and pressuring governments to adopt more comprehensive national strategies. However, approaches to HCV still vary widely between countries.
16. While every effort has been taken to verify the accuracy
of this information, The Economist Intelligence Unit
Ltd. cannot accept any responsibility or liability
for reliance by any person on this report or any of
the information, opinions or conclusions set out
in this report.
This report was commissioned and funded by Janssen
Pharmaceutica NV. The views and opinions of the
authors are not necessarily those of Janssen.